1513P Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib

P Sobczuk,E Bylina,A Klimczak A Klimczak,P Rutkowski

doi:10.1016/j.annonc.2022.07.1616

1513P Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib

P Sobczuk, E Bylina + Show 2 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1616

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: The Maria Sklodowska-Curie National Research Institute of Oncology

#Gastrointestinal Stromal Tumors #Long-term Treatment Outcomes In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

GISTs are driven by genetic aberrations, mostly observed within KIT and PDGFRA genes. Standard first-line therapy for inoperable/metastatic GIST includes imatinib. The presence of specific genetic alterations may impact imatinib efficacy and patients' survival. We aimed to analyze the impact of KIT and PDGFR mutation in patients with GIST treated in the first line with imatinib in two cohorts according to anatomical location.

Full Text